Abstract
In 12 healthy volunteers who received orally 100, 200, 300, 400 and 600 mg mexiletine at weekly intervals, the maximum plasma concentration of mexiletine and AUC increased linearly with the dose of mexiletine. Between doses there were no significant differences in the values for clearance and volume of distribution of mexiletine but there were for plasma elimination half-life. These results indicate that the kinetics of mexiletine are linear.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beckett A. H., Chidomere E. C. The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J. 1977;53 (Suppl 1):60–68. [PubMed] [Google Scholar]
- Campbell N. P., Kelly J. G., Adgey A. A., Shanks R. G. The clinical pharmacology of mexiletine. Br J Clin Pharmacol. 1978 Aug;6(2):103–108. doi: 10.1111/j.1365-2125.1978.tb00833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chew C. Y., Collett J., Singh B. N. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs. 1979 Mar;17(3):161–181. doi: 10.2165/00003495-197917030-00003. [DOI] [PubMed] [Google Scholar]
- Kobari T., Itoh T., Hirakawa T., Namekawa H., Suzuki T., Satoh T., Iida N., Ohtsu F., Hayakawa H. Dose-dependent pharmacokinetics of aprindine in healthy volunteers. Eur J Clin Pharmacol. 1984;26(1):129–131. doi: 10.1007/BF00546721. [DOI] [PubMed] [Google Scholar]
- Prescott L. F., Pottage A., Clements J. A. Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):50–55. [PubMed] [Google Scholar]
- Richens A., Dunlop A. Serum-phenytoin levels in management of epilepsy. Lancet. 1975 Aug 9;2(7928):247–248. doi: 10.1016/s0140-6736(75)90962-9. [DOI] [PubMed] [Google Scholar]